IgA肾病中蛋白尿与eGFR治疗效应的随机试验荟萃分析
该系统评价与荟萃分析检索了MEDLINE和Embase至2025年5月21日,纳入14项2b/3期多中心随机安慰剂对照试验,评估四类药物治疗IgA肾病对蛋白尿和eGFR斜率的影响。结果显示所有药物类别均降低蛋白尿并改善eGFR斜率,但效应存在异质性,皮质类固醇尤其高剂量时增加严重不良事件风险。
要点
- 所有四类药物均降低IgA肾病患者蛋白尿并减缓eGFR下降,但效应幅度因药物类别而异。
- 非免疫治疗、皮质类固醇、B细胞调节剂和补体抑制剂在蛋白尿和eGFR斜率上显示不同效应。
- 皮质类固醇尤其高剂量增加严重不良事件风险,其他药物类别一般耐受良好。
核心结论
- 所有四类药物均改善IgA肾病的肾脏结局,有证据表明对蛋白尿和eGFR斜率的效应存在差异。
- 不同疗法的机制和效应不同提示联合治疗的潜力,但个体最佳联合方案尚待确定。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE和Embase数据库自建库至2025年5月21日。
- 纳入2b期和3期多中心、随机、安慰剂对照试验,入组IgA肾病患者,报告蛋白尿和/或eGFR斜率的治疗效应。
- 共纳入14项试验,其中13项(93%)报告蛋白尿结局,7项(50%)报告eGFR结局。
- 试验分为四类药物:非免疫治疗、皮质类固醇、B细胞调节剂和补体抑制剂。
- 使用随机效应荟萃分析汇总总体及按药物类别的治疗效应。
主要发现
- 所有疗法均降低蛋白尿,效应幅度因类别而异:非免疫治疗−34%,皮质类固醇−51%,B细胞调节剂−45%,补体抑制剂−35%(异质性P<0.001)。
- 报告至少12个月eGFR斜率的试验显示所有药物类别均有获益,但效应可能因类别而异。
- eGFR斜率的绝对和相对效应:非免疫治疗为每年1.1 ml/min per 1.73 m2和−28%,皮质类固醇为每年2.3 ml/min per 1.73 m2和−52%,B细胞调节剂为每年4.3 ml/min per 1.73 m2和−73%(异质性P=0.03)。
- 皮质类固醇尤其高剂量增加严重不良事件风险,其他药物类别一般耐受良好。
关键数值与推荐
- 非免疫治疗降低蛋白尿−34%,皮质类固醇−51%,B细胞调节剂−45%,补体抑制剂−35%(异质性P<0.001)。
- 非免疫治疗eGFR斜率绝对效应每年1.1 ml/min per 1.73 m2,相对效应−28%。
- 皮质类固醇eGFR斜率绝对效应每年2.3 ml/min per 1.73 m2,相对效应−52%。
- B细胞调节剂eGFR斜率绝对效应每年4.3 ml/min per 1.73 m2,相对效应−73%(异质性P=0.03)。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 蛋白尿和eGFR结局分别仅在13项(93%)和7项(50%)试验中可用。
- 长期临床肾脏结局和安全性数据尚待获取。
- 个体最佳联合治疗方案尚待确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Existing and novel therapies reduce proteinuria and slow eGFR rate of decline in IgA nephropathy, with some heterogeneity across drug classes. Benefits and limitations of each drug class must be considered, and longer-term Phase 3 data on several therapies are awaited. Emerging data support the potential of novel therapies to improve kidney outcomes in IgA nephropathy in the near future. BACKGROUND: Substantial advances have been made in therapeutics for IgA nephropathy. We conducted a systematic review and meta-analysis to evaluate the comparative efficacy and safety of existing and novel IgA nephropathy therapies. METHODS: We searched MEDLINE and Embase databases from inception to May 21, 2025, for Phase 2b and 3 multicenter, randomized, placebo-controlled trials enrolling patients with IgA nephropathy that reported treatment effects on proteinuria and/or eGFR slope. Trials were categorized into four drug classes: Nonimmunologic therapies, corticosteroids, B-cell modulating agents, and complement inhibitors. Treatment effects on proteinuria and eGFR slope were pooled overall and by drug class using random-effects meta-analysis. RESULTS: Fourteen trials were identified of which proteinuria and eGFR outcomes were available in 13 trials (93%) and seven trials (50%), respectively. Pooled data demonstrated all therapies reduced proteinuria, although the magnitude of effect varied across classes: −34% with nonimmunologic therapies, −51% with corticosteroids, −45% with B-cell modulating agents, and −35% with complement inhibitors (P heterogeneity <0.001). Data from trials reporting eGFR slope over a minimum of 12 months indicated benefits for all drug classes, but again with some evidence that effects varied by class. The absolute and relative effect on eGFR slope was 1.1 ml/min per 1.73 m2 per year and −28% with nonimmunologic therapies, 2.3 ml/min per 1.73 m2 per year and −52% with corticosteroids, and 4.3 ml/min per 1.73 m2 per year and −73% with B-cell modulating agents (P heterogeneity = 0.03). Corticosteroids, particularly at higher doses, increased the risk of serious adverse events, but other drug classes were generally well tolerated. Longer-term data on clinical kidney outcomes and safety are awaited. CONCLUSIONS: All four drug classes improve kidney outcomes in IgA nephropathy, with some evidence of differential effects on proteinuria and eGFR slope. The varying mechanisms and effects of different therapies suggest a potential for combination therapy, although selection of the optimal combination of therapies for individuals remain to be determined.
引用
- Kim D, Neuen BL, Perkovic V, et al. Effects of Therapies on Proteinuria and eGFR in IgA Nephropathy: Meta-Analysis of Randomized Trials. Clin J Am Soc Nephrol. 2025. PMID: 40928891. doi:10.2215/CJN.0000000839
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。